Table 2

Risk of all types of cancer in the calcium channel blocker (CCB) cohort compared to the non-CCB and the non-CCB antihypertensive (AHT) drugs cohorts

CohortNumber of cancersNumber of person-yearsCancer incidence rates (per 1000 person-years)CCB vs non-CCBCCB vs AHT
Crude HRAdjusted HRCrude HRAdjusted HR
(95% CI)(95% CI)
CCB14 588883 80316.511.03 (1.01 to 1.05)0.88 (0.86 to 0.89)*1.56 (1.53 to 1.61)1.01 (0.98 to 1.04)
Non-CCB43 9922 792 94815.751.00 (reference)1.00 (reference)
AHT9754918 80110.621.00 (reference)1.00 (reference)
  • *p<0.001. HR obtained from multivariate Cox proportional hazard analyses including age at index date, gender, smoking status, body mass index, alcohol consumption, diagnoses of diabetes, hypertension, arrhythmia, angina or heart failure, and use of statins or aspirin.